best practices for 505(b)(2) and anda applicants
Published 3 years ago • 3.4K plays • Length 39:07Download video MP4
Download video MP3
Similar videos
-
18:34
patent dispute and best practices for 505(b)(2) and anda applicants – panel discussion
-
20:08
505(b)(2) nda or anda? (10of28) generic drugs forum – apr. 3-4, 2019
-
11:32
determining whether to submit an anda or a 505(b)(2) application (12of27) generic drugs forum 2018
-
59:15
efficient use of 505 b2 pathway to enter us market
-
8:00
fda 505(b)(2) applications seminar part i: where does a 505(b)(2) fit?
-
54:12
best practices for topical generic product development and anda submission – session 2
-
39:41
referencing approved drug products in anda submissions
-
13:58
guidance for industry: referencing approved drug products in anda submissions
-
55:29
the 505(b)(2) nda pathway - an innovative fda strategy that everyone should understand webinar
-
8:31
fda 505(b)(2) applications seminar part iv: the thin line between a 505(j) and 505(b)(2)
-
4:25
fda expectations for 505(b)(2) regulatory pathway for new drugs
-
5:32
fda 505(b)(2) applications seminar part vi: recent statistics on 505(b)(2) ndas
-
58:05
best practices for topical generic product development & anda submission–session 3, closing remarks
-
1:02:35
anda vs. 505(b)(2): when and why? webinar
-
14:31
fda 505(b)(2) applications seminar part viii: q&a and discussion of 505(b)(2) applications
-
19:33
us fda. 505(b)(2)
-
9:30
fda 505(b)(2) applications seminar part ii: the regulatory pathway
-
6:13
fda 505(b)(2) applications seminar part iii: developing a 505(b)(2) application
-
22:52
anda postapproval changes: best practices and strategies to avoid common quality assessment issues